
Perry Baromedical
Multiplace Series
$150,000 - $400,000+
From concussions to severe TBI — what the clinical evidence says about HBOT for brain recovery.
Key Takeaways
Traumatic brain injury (TBI) ranges from mild concussions to severe brain damage, affecting an estimated 69 million people worldwide each year. Even mild TBI (mTBI) can cause persistent symptoms — headaches, cognitive impairment, mood changes, sleep disruption — that last months or years. Standard treatment is limited to rest, rehabilitation, and symptom management. HBOT has emerged as one of the most-studied alternative interventions for TBI, with over 40 published clinical studies exploring its effects on brain repair and neuroplasticity.
HBOT increases dissolved oxygen in blood plasma by 10–15x normal levels, penetrating damaged brain tissue where red blood cells cannot reach due to impaired microcirculation. This oxygen surge triggers multiple repair mechanisms: it reduces cerebral edema and neuroinflammation, stimulates angiogenesis (new blood vessel formation in damaged areas), promotes neurogenesis and stem cell mobilization, and reactivates dormant neurons in the penumbra — the area of brain tissue surrounding the injury that is metabolically impaired but not destroyed. Imaging studies (SPECT scans) have documented measurable improvements in brain perfusion after HBOT protocols.
Recommended Protocol
Pressure
1.5–2.0 ATA
Sessions
40–80 sessions
Duration
60 minutes per session
TBI is one of the most extensively researched off-label uses of HBOT. A 2012 study by Harch et al. demonstrated significant improvement in cognitive function, PTSD symptoms, and SPECT brain imaging in military veterans with blast-induced mTBI after 40 sessions at 1.5 ATA. The Israeli Defense Forces have conducted multiple studies showing HBOT benefits for chronic TBI. A 2020 Lancet meta-analysis found statistically significant improvements in neurological outcomes. However, the evidence remains controversial because some sham-controlled trials (using 1.2 ATA as "placebo") also showed improvement — leading to debate about whether even low-pressure exposure has therapeutic value. The consensus: HBOT at 1.5–2.0 ATA produces measurable neurological improvements, but large-scale definitive trials are still needed.
Off-Label Use
Traumatic Brain Injury (TBI) is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Based on the protocol requirements — minimum 1.5 ATA, Clinical Grade or Advanced Wellness tier. Sorted by clinical credibility score.

Perry Baromedical
$150,000 - $400,000+

Perry Baromedical
$50,000 - $90,000

Perry Baromedical
$55,000 - $95,000

Perry Baromedical
$65,000 - $110,000

Perry Baromedical
$100,000 - $160,000

Perry Baromedical
$80,000 - $130,000
Research shows benefit even years after injury. The Sagol Center studies have treated patients 1–5+ years post-TBI with documented brain perfusion improvements on SPECT imaging. The penumbra — metabolically impaired but living brain tissue — can potentially be reactivated regardless of time elapsed. Earlier treatment may yield better results, but late treatment is not futile.
Yes, post-concussion syndrome is one of the most common reasons people seek HBOT. Multiple studies show improvements in headaches, cognitive function, and return-to-baseline time. Some professional sports teams use HBOT as part of their concussion recovery protocol. Protocols typically use 1.5–2.0 ATA for 20–40 sessions.
No. TBI is not on the FDA's approved indications list for HBOT, so insurance generally does not cover it. The VA has funded HBOT research for veteran TBI but does not routinely offer it as treatment. Out-of-pocket cost for a 40-session protocol at a clinic is approximately $6,000–$12,000.
Most clinical studies use 1.5 ATA or 2.0 ATA. The Harch protocol uses 1.5 ATA with 100% oxygen. Israeli military studies have used 2.0 ATA. Both show benefit. Lower pressures (1.3 ATA) are debated — some sham-controlled trials found even the "placebo" group at 1.2 ATA showed improvement, suggesting there may be a dose-response curve where even mild pressures have some effect.
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Use our filterable directory to find chambers that match your protocol requirements.